Results 11 to 20 of about 68,339 (362)

Study of Proper use of Inhalational Devices by Bronchial Asthma or Copd Patients Attending a Tertiary Care Hospital [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2014
Objective: To examine the frequency of proper use of inhalation devices and influence of age and training on it. Materials and Methods: One hundred and five subjects of bronchial asthma and Chronic Obstructive Pulmonary Disease (COPD); aged between ...
Avijit Ganguly   +5 more
doaj   +1 more source

Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study [PDF]

open access: yes, 2016
Background: Serious inhaler technique errors can impair drug delivery to the lungs. This randomised, crossover, open-label study evaluated the proportion of patients making predefined serious errors with Pulmojet compared with Diskus and Turbohaler dry ...
A Palander   +52 more
core   +2 more sources

A study to monitor errors in use of inhalation devices in patients of mild-to-moderate bronchial asthma in a tertiary care hospital in Eastern India

open access: yesPerspectives in Clinical Research, 2022
Context: Bronchial asthma is a chronic respiratory disorder which affects over 300 million people worldwide. Inhalation pharmacotherapy is the cornerstone in treatment of asthma, which is administered using inhaler devices.
Neha Akhoon, D B S. Brashier
doaj   +1 more source

Switching patients from other inhaled corticosteroid devices to the Easyhaler(®) : historical, matched-cohort study of real-life asthma patients [PDF]

open access: yes, 2014
Peer reviewedPublisher ...
Gould, Shuna   +5 more
core   +1 more source

Comparing Inhaler Use Technique Based on Inhaler Type in Elderly Patients with Respiratory Disease [PDF]

open access: yesTuberculosis and Respiratory Diseases, 2021
Background The aim of this study was to investigate inhaler device handling in elderly patients. Inhaler devices with respect to misuse and error correction were also compared.
Ha Youn Lee   +7 more
doaj   +1 more source

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: A randomized non-inferiority study [PDF]

open access: yes, 2018
Background: Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in patients with chronic obstructive ...
Birk, Ruby   +5 more
core   +2 more sources

Inappropriate Peak Inspiratory Flow Rate in the Patients with Stable Chronic Obstructive Pulmonary Disease in Korea [PDF]

open access: yesTuberculosis and Respiratory Diseases
Background While inhalation therapy efficacy hinges on attaining proper peak inspiratory flow rate (PIFR), the prevalence of inappropriate PIFR among patients with chronic obstructive pulmonary disease (COPD) remains unstudied in Korea.
Seong Hwan Youn   +5 more
doaj   +1 more source

Exploring the role of quantitative feedback in inhaler technique education : a cluster-randomised, two-arm, parallel-group, repeated-measures study [PDF]

open access: yes, 2014
Peer reviewedPublisher ...
Amin Basheti, Iman   +3 more
core   +2 more sources

Inhaled corticosteroids versus long-acting beta -agonists for chronic obstructive pulmonary disease (Review). [PDF]

open access: yes, 2011
Long-acting beta(2)-agonists and inhaled corticosteroids can be used as maintenance therapy by patients with moderate to severe chronic obstructive pulmonary disease. These interventions are often taken together in a combination inhaler.
Agarwal   +105 more
core   +2 more sources

Establishing the relationship of inhaler satisfaction, treatment adherence, and patient outcomes : A prospective, real-world, cross-sectional survey of US adult asthma patients and physicians [PDF]

open access: yes, 2015
Date of Acceptance: 26/06/2015 Acknowledgements The disease-specific program, on which the analyses were based, was designed and run by Adelphi Real World. The program was supported by a number of pharmaceutical companies, including Meda Pharmaceuticals.
Harrow, Brooke   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy